Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke

NCT ID: NCT04973332

Last Updated: 2022-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 218 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-08
• Study Completion Date: 2022-06-24

Brief Summary

A prospective, multicenter, randomized controlled, non-inferiority study to investigate the effectiveness and safety of SINOMED SR for endovascular treatment of acute ischemic stroke

Detailed Description

This is a multicenter, prospective, randomized, 1:1, controlled trial with blinded outcome assessment assessing non-inferiority of SINOMED SR compared to Solitaire FR. The trial aims to randomize 220 patients 1:1 to receive SINOMED SR or Solitaire FR.The primary outcome is the Success rate of immediate recanalization.

Conditions

Ischemic Stroke, Acute; Brain Diseases; Cerebrovascular Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Thrombectomy-SINOMED SR

Patients diagnosed with acute ischemic stroke within 24 hours from the onset of the stroke to the completion of femoral artery puncture, regardless of whether intravenous thrombolysis has been performed. Intracranial thrombectomy stents can be used to remove the thrombus in the large vessels of the brain in patients with ischemic stroke To restore blood flow.

Group Type: EXPERIMENTAL

Intracranial thrombectomy stent

Intervention Type: DEVICE

Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset

Thrombectomy-Solitaire FR

Intracranial thrombectomy was performed with a control product（name:Solitaire FR）

Group Type: ACTIVE_COMPARATOR

Intracranial thrombectomy stent

Intervention Type: DEVICE

Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset

Interventions

Intracranial thrombectomy stent

Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. 18 years old or more;

2. NIHSS≥6 during randomization;

3. Pre-onset MRS < 2;

4. Acute ischemic stroke was diagnosed;

5. Within 24 hours from the onset of stroke to the completion of femoral artery puncture, regardless of whether intravenous thrombolysis has been performed;The time point of stroke onset was defined as the time point at which the patient's last normal condition was known;

6. The subject (or his/her guardian) agrees to participate in this study and signs the informed consent.

1. When it is less than 6h (inclusive) from the onset of stroke to the completion of femoral artery puncture, patients should be examined by cranial CT or MR;

2. When it is more than 6h but less than 24h (inclusive) from the onset of stroke to the completion of femoral artery puncture, brain CT or MR should be performed and Aspects ≥6 points should be satisfied.(If immediate CT perfusion imaging or MR perfusion imaging is feasible, CTP or MRP is recommended to assist in the assessment of the infarct core, and Aspects ≥6 points shall also be satisfied);

3. DSA angiography showed acute intracranial arterial occlusion, including intracranial segment of internal carotid artery (C4-C7), middle cerebral artery (M1/M2), basilar artery and intracranial segment of vertebral artery (V4).

Exclusion Criteria

1. Neither MRI nor CT can be performed;

2. Hemorrhagic stroke or major ischemic stroke within 6 months before enrollment;

3. Severe persistent hypertension that cannot be controlled by venous hypotension, i.e., patients with SBP persistent >185mmHg and/or DBP persistent >110mmHg;

4. Suppose septic emboli or suspected bacterial endocarditis;

5. Renal failure, defined as: creatinine >3.0mg/dL(264 mol/L);

6. Blood glucose < 2.78mmol/L (50mg/dL) or >22.20mmol/L (400mg/dL);

7. decreased platelet count (< 40×109/L);

8. Known bleeding tendency, defect of coagulation factor, taking anticoagulants and INR > 3.0;

9. Pregnant or lactating women;

10. known to be severely allergic to contrast agents and known to be allergic to nickel materials;

11. The presence of diseases that may affect the assessment of neurological function (such as neurological diseases, mental diseases, etc.);

12. with heart, lung, liver function failure or other serious diseases to interventional surgery;

13. Participating in clinical trials of other drugs or devices;

14. Life expectancy less than 6 months;

15. Other conditions judged by the researcher to be unsuitable for inclusion.

1. CT or MR imaging evidence of intracranial hemorrhage or known bleeding tendency;

2. CT/MR/DSA showed > occlusion (such as bilateral internal carotid artery occlusion at the same time, or anterior circulation and posterior circulation intracranial vessels occlusion at the same time, or internal carotid intracranial and extracranial segments occlusion at the same time);

3. Carotid artery dissection, carotid initial occlusion or arteritis;

4. The vascular circuitry was severe, and the intracranial thrombectomy stent was difficult to reach the target position.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sinomed Neurovita Technology Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xinfeng Liu

Role: PRINCIPAL_INVESTIGATOR

General Hospital of Eastern Theater Command, PLA

Locations

General Hospital of Eastern Theater Command, PLA

Nanjing, , China

Countries

China

References

Huo S, Gao J, Lv Q, Xie M, Wang H, Zhang X, Xie Y, Wu M, Liu R, Liu X, Yuan K, Ye R. Trajectories of stroke severity and functional outcomes after endovascular treatment in ischemic stroke: A post hoc analysis of a randomized controlled trial. Clin Neurol Neurosurg. 2024 Apr;239:108248. doi: 10.1016/j.clineuro.2024.108248. Epub 2024 Mar 16.

Reference Type: DERIVED

PMID: 38507987 (View on PubMed)

Other Identifiers

SINOMED SR

Identifier Type: -

Identifier Source: org_study_id